- Home
- BKV vs COGT Comparison
BKV vs COGT Comparison
Compare BKV & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKV
- COGT
- Stock Information
- Founded
- BKV 2015
- COGT 2014
- Country
- BKV United States
- COGT United States
- Employees
- BKV N/A
- COGT N/A
- Industry
- BKV Oil & Gas Production
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- BKV Energy
- COGT Health Care
- Exchange
- BKV Nasdaq
- COGT Nasdaq
- Market Cap
- BKV 1.9B
- COGT 2.3B
- IPO Year
- BKV 2024
- COGT 2018
- Fundamental
- Price
- BKV $20.75
- COGT $16.34
- Analyst Decision
- BKV Buy
- COGT Strong Buy
- Analyst Count
- BKV 7
- COGT 12
- Target Price
- BKV $27.57
- COGT $22.00
- AVG Volume (30 Days)
- BKV 412.7K
- COGT 2.3M
- Earning Date
- BKV 11-10-2025
- COGT 11-11-2025
- Dividend Yield
- BKV N/A
- COGT N/A
- EPS Growth
- BKV N/A
- COGT N/A
- EPS
- BKV N/A
- COGT N/A
- Revenue
- BKV $756,795,000.00
- COGT N/A
- Revenue This Year
- BKV $48.60
- COGT N/A
- Revenue Next Year
- BKV $24.38
- COGT N/A
- P/E Ratio
- BKV N/A
- COGT N/A
- Revenue Growth
- BKV 13.79
- COGT N/A
- 52 Week Low
- BKV $15.00
- COGT $3.72
- 52 Week High
- BKV $26.78
- COGT $17.15
- Technical
- Relative Strength Index (RSI)
- BKV 43.48
- COGT 61.74
- Support Level
- BKV $20.17
- COGT $14.20
- Resistance Level
- BKV $21.02
- COGT $16.56
- Average True Range (ATR)
- BKV 0.82
- COGT 0.83
- MACD
- BKV -0.09
- COGT -0.10
- Stochastic Oscillator
- BKV 30.37
- COGT 72.54
About BKV BKV Corporation Common Stock
BKV Corp is a growth-driven energy company. Its core business is production of natural gas from its owned and operated upstream businesses. It operates in four business lines: natural gas production, natural gas gathering, processing and transportation (natural gas midstream business), power generation and carbon capture, utilization, and sequestration (CCUS).
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.